Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
    • Special Collections
  • EDITORIAL BOARD
    • Editorial Board
    • ECR Advisory Board
    • Journal Staff
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
    • Accessibility
  • SUBSCRIBE

User menu

  • Log out
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Neuroscience
  • Log out
  • Log in
  • My Cart
Journal of Neuroscience

Advanced Search

Submit a Manuscript
  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
    • Special Collections
  • EDITORIAL BOARD
    • Editorial Board
    • ECR Advisory Board
    • Journal Staff
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
    • Accessibility
  • SUBSCRIBE
PreviousNext
Featured ArticleArticles, Neurobiology of Disease

1α,25-Dihydroxyvitamin D3 Reduces Cerebral Amyloid-β Accumulation and Improves Cognition in Mouse Models of Alzheimer's Disease

Matthew R. Durk, Kyung Han, Edwin C. Y. Chow, Rosemary Ahrens, Jeffrey T. Henderson, Paul E. Fraser and K. Sandy Pang
Journal of Neuroscience 21 May 2014, 34 (21) 7091-7101; https://doi.org/10.1523/JNEUROSCI.2711-13.2014
Matthew R. Durk
1Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, Toronto, Ontario, Canada, M5S 3M2,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kyung Han
3Tanz Centre for Research in Neurodegenerative Diseases, Krembil Discovery Tower, Toronto, Ontario, Canada, M5T 2S8
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edwin C. Y. Chow
1Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, Toronto, Ontario, Canada, M5S 3M2,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosemary Ahrens
3Tanz Centre for Research in Neurodegenerative Diseases, Krembil Discovery Tower, Toronto, Ontario, Canada, M5T 2S8
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey T. Henderson
1Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, Toronto, Ontario, Canada, M5S 3M2,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul E. Fraser
2Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada, M5S 3H2, and
3Tanz Centre for Research in Neurodegenerative Diseases, Krembil Discovery Tower, Toronto, Ontario, Canada, M5T 2S8
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. Sandy Pang
1Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, Toronto, Ontario, Canada, M5S 3M2,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Distribution of Vdr and P-gp in 8-week-old C57BL/6 mouse brains and effects of 1,25(OH)2D3 treatment on P-gp levels in brain regions. a, P-gp (green), along with Vdr (red), was expressed in brain capillaries within the cerebral cortex. Scale bars, 100 μm. Vdr levels were highest in the hippocampus and cortex (b), and P-gp levels were elevated mostly in the hippocampal and cortical regions after 1,25(OH)2D3 treatment (c) (for striatum, n = 4; for other regions, n = 6). Data are mean ± SEM. Differences among groups were compared using one-way ANOVA, and p values were determined by Bonferroni's multiple comparisons test. PFC, Prefrontal cortex; STR, striatum; HC, hippocampus; CER, cerebellum; OLB, olfactory bulb.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Changes in 1,25(OH)2D3 levels and Vdr target gene expression during the 1,25(OH)2D3 treatment period in control and 1,25(OH)2D3-treated 8-week-old C57BL/6 mice. a, After treatment with repeated doses of 1,25(OH)2D3, brain levels (black symbols) of 1,25(OH)2D3 rose and fell in unison with those in plasma [gray symbols; from a previous publication (Chow et al., 2013)]; open and filled symbols represent levels in brains of untreated and treated mice, respectively. The lines connect the mean levels. b, Basal mRNA levels of Vdr target genes, Cyp24a1 and Mdr1a, were relatively unaltered in vehicle-treated animals but were increased after treatment. Cyp24a1 levels rose and fell sharply, but Mdr1a mRNA levels were sustained during the dosing period (n = 2–4 for each time point).

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Vitamin D (Vit D) deficiency lowers plasma 1,25(OH)2D3 and cerebral P-gp expression. a, C57BL/6 mice (8 weeks old) that were fed a vitamin D-deficient diet exhibited significantly lower (75%) plasma 1,25(OH)2D3 levels after 6 weeks of the diet (n = 4 for samples at 2, 4, and 6 weeks). Replenishment of the vitamin D-deficient mice after week 6 with dietary vitamin D or 1,25(OH)2D3 elevated plasma 1,25(OH)2D3 levels, albeit not to basal levels (n ≥ 6). b, Mdr1a mRNA expression and P-gp protein levels were fully restored on replenishment with 1,25(OH)2D3. For vitamin D-deficient and vitamin D-sufficient mice, n = 6. Data are mean ± SEM; a one-way ANOVA was used to evaluate differences between groups, with p values determined by Bonferroni's multiple comparisons test.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    1,25(OH)2D3 treatment induces P-gp in 10-week-old Tg2576 mice (a) and reduces soluble hAβ1–40 and hAβ1–42 in the brain (b). N/D denotes that levels were below detection limits. For Tg2576 mice, n = 5; for non-Tg mice, n = 6. A one-way ANOVA was used to evaluate differences in Mdr1a/P-gp between groups, with p values determined by Bonferroni's multiple comparisons test. To compare Aβ levels between treated and control Tg2576 mice, p values were determined by Student's two-tailed t test.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Relative brain Mdr1a mRNA and P-gp protein levels (a) and brain concentrations of soluble and insoluble hAβ1–40 and hAβ1–42 (b) in non-Tg and TgCRND8 mice (at 4 months) after treatment with 1,25(OH)2D3 or vehicle for 8 weeks. Significant reduction of soluble hAβ1–42 and insoluble hAβ1–40 and hAβ1–42 was observed after 1,25(OH)2D3 treatment. N/D denotes that levels were below detection limits. For TgCRND8 mice, n ≥ 7; for non-Tg mice, n ≥ 4. Data are mean ± SEM; a one-way ANOVA was used to evaluate differences in Mdr1a/P-gp between groups, with p values determined by Bonferroni's multiple comparisons test. To compare Aβ levels between treated and control TgCRND8 mice, p values were determined by Student's two-tailed t test.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    1,25(OH)2D3 treatment decreases dense and diffuse amyloid plaques in TgCRND8 mice. a, Representative images of brains of vehicle-treated and 1,25(OH)2D3-treated TgCRND8 mice after long-term treatment and significant decreases in dense and diffuse amyloid plaques in cortex and hippocampus. For each group, n = 7 mice. Every fifth section of 25 sections from each brain were stained and quantified. Data are mean ± SEM; p values were determined by Student's two-tailed t test. Scale bars, 1 mm. b, Resorufin staining in the cerebral cortex. bi, bii, Patterns of resorufin binding observed in cerebral arteries of TgCRND8 mice at 17 weeks of age. Exterior surface of cerebral artery (bi) and cross-section of cerebral artery demonstrating interspersed laminar stripes of resorufin distribution on abluminal surface (bii). biii–bv, Resorufin staining seen in cortex of vehicle- treated animals; bvi–bviii, resorufin staining observed in cortex of 1,25(OH)2D3-treated animals. Although statistically significant differences in resorufin staining were not observed in cerebral vasculature, a diminution of resorufin-positive neuritic plaques was noted in 1,25(OH)2D3-treated animals (arrowheads). Scale bars (in iii–viii), 100 mm. For each group, n = 5 mice. For 105 sections, the first four of every 30 sections from each brain was stained and quantified. Data are mean ± SEM; p values were determined by Student's two-tailed t test.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    Fear conditioning studies: frequency of freezing behavior is partially restored in TgCRND8 mice that received 1,25(OH)2D3 treatment. Data are mean ± SEM percentage of time mice exhibited freezing behavior before and after the CS. Vehicle-treated non-Tg mice, n = 10; 1,25(OH)2D3-treated non-Tg mice, n = 8; vehicle-treated TgCRND8 mice, n = 8; and 1,25(OH)2D3-treated TgCRND8 mice, n = 10. A one-way ANOVA was used to evaluate differences between groups, with p values determined by Bonferroni's multiple comparisons test.

  • Figure 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 8.

    1,25(OH)2D3 treatment increases P-gp in 20-week-old TgCRND8 mice (a) and reduces soluble hAβ1–40 and hAβ1–42 in the brain (b). Data are mean ± SEM. For all groups, n = 4. A one-way ANOVA was used to evaluate differences between groups, with p values determined by Bonferroni's multiple comparisons test.

Tables

  • Figures
    • View popup
    Table 1.

    Comparison of cerebral hAβ levels in vehicle-treated and 1,25(OH)2D3-treated Tg mice

    Vehicle or 1,25(OH)2D3 treatment (μg/kg, i.p.)Soluble Aβ concentration in brain (ng/g wet weight)Insoluble Aβ concentration in brain (ng/g wet weight)
    hAβ1–40hAβ1–42hAβ1–42/hAβ1–40 ratiohAβ1–40hAβ1–42hAβ1–42/hAβ1–40 ratio
    Tg2576 (5 males per group), began treatment at 10 weeks old, 11 weeks old when killed
        0 (q2d × 4)39.1 ± 4.2511.1 ± 0.2400.276 ± 0.0169NPbNPNP
        2.5 (q2d × 4)15.4 ± 2.15*5.82 ± 0.891*0.357 ± 0.0226NPNPNP
    TgCRND8 (4 males, 3–4 females per group), began treatment at 9 weeks old, 17 weeks old when killed
        0 (q3d × 19)872 ± 33.73360 ± 1223.65 ± 0.176923 ± 66.74640 ± 1434.75 ± 0.247
        2.5 (q3d × 19)618 ± 18.7*2240 ± 153*3.39 ± 0.196514 ± 69.0*3870 ± 133*7.16 ± 0.361*
    TgCRND8 (4 females per group), began treatment at 20 weeks old, 21 weeks old when killed
        0 (q2d × 4)1060 ± 25.92920 ± 2022.78 ± 0.2193850 ± 93118000 ± 17003.83 ± 0.166
        2.5 (q2d × 4)675 ± 54.3**1970 ± 130**3.04 ± 0.4174710 ± 28216500 ± 8783.54 ± 0.312
        2.5 (q2d × 4) + 10 mg/kg elacridar (q12h × 8)1240 ± 27.6***4700 ± 214***3.78 ± 0.107***6030 ± 23820400 ± 4433.40 ± 0.198
    • hAβ levels were not detected in non-Tg mice. NP, Not present.

    • ↵*p < 0.05 for 1,25(OH)2D3 treatment compared with vehicle treatment, Student's two-tailed t test.

    • ↵**p < 0.05 for 1,25(OH)2D3 treatment compared with vehicle treatment, one-way ANOVA with Bonferroni's multiple comparisons test.

    • ↵***p < 0.05 for elacridar plus 1,25(OH)2D3 treatment compared with vehicle treatment, one-way ANOVA with Bonferroni's multiple comparisons test.

Back to top

In this issue

The Journal of Neuroscience: 34 (21)
Journal of Neuroscience
Vol. 34, Issue 21
21 May 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Advertising (PDF)
  • Ed Board (PDF)
Email

Thank you for sharing this Journal of Neuroscience article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
1α,25-Dihydroxyvitamin D3 Reduces Cerebral Amyloid-β Accumulation and Improves Cognition in Mouse Models of Alzheimer's Disease
(Your Name) has forwarded a page to you from Journal of Neuroscience
(Your Name) thought you would be interested in this article in Journal of Neuroscience.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
1α,25-Dihydroxyvitamin D3 Reduces Cerebral Amyloid-β Accumulation and Improves Cognition in Mouse Models of Alzheimer's Disease
Matthew R. Durk, Kyung Han, Edwin C. Y. Chow, Rosemary Ahrens, Jeffrey T. Henderson, Paul E. Fraser, K. Sandy Pang
Journal of Neuroscience 21 May 2014, 34 (21) 7091-7101; DOI: 10.1523/JNEUROSCI.2711-13.2014

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Request Permissions
Share
1α,25-Dihydroxyvitamin D3 Reduces Cerebral Amyloid-β Accumulation and Improves Cognition in Mouse Models of Alzheimer's Disease
Matthew R. Durk, Kyung Han, Edwin C. Y. Chow, Rosemary Ahrens, Jeffrey T. Henderson, Paul E. Fraser, K. Sandy Pang
Journal of Neuroscience 21 May 2014, 34 (21) 7091-7101; DOI: 10.1523/JNEUROSCI.2711-13.2014
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Keywords

  • Alzheimer's
  • amyloid beta
  • blood-brain barrier
  • P-glycoprotein
  • vitamin D receptor

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

Articles

  • Memory Retrieval Has a Dynamic Influence on the Maintenance Mechanisms That Are Sensitive to ζ-Inhibitory Peptide (ZIP)
  • Neurophysiological Evidence for a Cortical Contribution to the Wakefulness-Related Drive to Breathe Explaining Hypocapnia-Resistant Ventilation in Humans
  • Monomeric Alpha-Synuclein Exerts a Physiological Role on Brain ATP Synthase
Show more Articles

Neurobiology of Disease

  • Sequence diversity and encoded enzymatic differences of monocistronic L1 ORF2 mRNA variants in the aged normal and Alzheimer’s disease brain
  • The Functional Anatomy of Nociception: Effective Connectivity in Chronic Pain and Placebo Response
  • A Novel Candidate Neuromarker of Central Motor Dysfunction in Childhood Apraxia of Speech
Show more Neurobiology of Disease
  • Home
  • Alerts
  • Follow SFN on BlueSky
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Issue Archive
  • Collections

Information

  • For Authors
  • For Advertisers
  • For the Media
  • For Subscribers

About

  • About the Journal
  • Editorial Board
  • Privacy Notice
  • Contact
  • Accessibility
(JNeurosci logo)
(SfN logo)

Copyright © 2025 by the Society for Neuroscience.
JNeurosci Online ISSN: 1529-2401

The ideas and opinions expressed in JNeurosci do not necessarily reflect those of SfN or the JNeurosci Editorial Board. Publication of an advertisement or other product mention in JNeurosci should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in JNeurosci.